Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company ShowcaseGlobeNewsWire • 05/15/24
Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational HighlightsGlobeNewsWire • 05/13/24
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsGlobeNewsWire • 04/01/24
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct OfferingGlobeNewsWire • 03/28/24
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi SyndromeGlobeNewsWire • 03/25/24
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024GlobeNewsWire • 03/19/24
Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of TherapyGlobeNewsWire • 03/07/24
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in HumansGlobeNewsWire • 03/05/24
Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor ConferenceGlobeNewsWire • 02/20/24
Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024GlobeNewsWire • 02/14/24
Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSDGlobeNewsWire • 02/12/24
New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA ApprovalAccesswire • 02/01/24
Tonix Pharmaceuticals Announces Research Indicating Pre-Existing Fibromyalgia-Type Symptoms May Increase the Risk of Developing Long COVIDGlobeNewsWire • 01/31/24
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya™ as Trade Name for TNX-102 SL for the Management of FibromyalgiaGlobeNewsWire • 01/29/24
Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P.GlobeNewsWire • 01/25/24
Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of TNX-102 SL in Second Positive Phase 3 Clinical Trial for the Management of FibromyalgiaGlobeNewsWire • 01/09/24
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in January: Focus is on TNX-102 SL for the Management of Fibromyalgia Following Positive Topline Results in Second Pivotal Phase 3 TrialGlobeNewsWire • 01/03/24
Tonix Pharmaceuticals Announces Registered Direct Offering of up to $144 MillionGlobeNewsWire • 12/20/23